including five of AstraZeneca’s patents on its blockbuster inhaler Symbicort. The company noted it reduced the list price of Symbicort at the start of this year. The change comes amid increasing ...

Today's decision marks the fourth Symbicort patent to be found either not infringed or invalid. In May, after Viatris and Kindeva won an appeal, AstraZeneca stipulated that the company's ...

AstraZeneca is in hot water with the U.K ... ruled that the Big Pharma made some serious errors of judgement for a Symbicort ad. The case was brought by an anonymous healthcare professional ...

Photo: Aaron M. Sprecher (AP) AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at ...

Mylan sued over generic of blockbuster AstraZeneca asthma drug Ruling ends one West Virginia case, another goes to trial in December (Reuters) - Viatris' Mylan Pharmaceuticals Inc cleared a hurdle ...

AstraZeneca substantially reduced the list price of SYMBICORT on January 1, 2024. The Company will continue to provide discounts and rebates off the list price to help patients afford its inhaled ...

Viatris announced the launch of Breyna ™ (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first generic version of AstraZeneca’s Symbicort ®. Breyna is a metered-dose ...

“Over the years, AstraZeneca has always been a pioneer ... And in this project, we were able to put our symbicort on health insurance so that patients even in the remote areas can also have ...

On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials assessed the efficacy and safety of ...